A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia

Aimen Naz; Taha Basit Ameen; Furqanullah Khalid; Abdul Raheem; Mohammad Bilal Abbasi; Syed Muhammad Sinaan Ali; Syed Illyas Ahmed; Maleeha Mehmood; Syeda Zainab Fatima Rizvi; Naeemullah Arbani; Muhammad Saleem Khuhro

doi:10.5455/IJMSPH.2026.v12.i1.2

2026, Vol: 12, Issue: 1

12 / 1Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Title Page

Original Research

Int J Med Sci Public Health. 2026; 12(1): 13-25

doi: 10.5455/IJMSPH.2026.v12.i1.2

A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia

Aimen Naz, Taha Basit Ameen, Furqanullah Khalid, Abdul Raheem, Mohammad Bilal Abbasi, Syed Muhammad Sinaan Ali, Syed Illyas Ahmed, Maleeha Mehmood, Syeda Zainab Fatima Rizvi, Naeemullah Arbani, Muhammad Saleem Khuhro.

Abstract
Background:
Methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections (BSIs) are a major global cause of morbidity and mortality. Although standard-of-care (SOC) treatments, such as oxacillin, nafcillin, and cefazolin, are effective, they require frequent dosing and prolonged hospital stays. Ceftriaxone, with its once-daily dosing, offers a potentially more convenient alternative. However, its efficacy and safety in treating MSSA-BSIs remain unclear.

Aim:
This systematic review and meta-analysis aimed to compare the efficacy and safety of ceftriaxone versus standard therapy across diverse clinical settings in adult patients with MSSA-BSIs.

Methods:
A comprehensive literature search was conducted across PubMed, Embase, and Scopus up to March 15, 2024. Randomized controlled trials and observational studies comparing ceftriaxone with SOC for MSSA-BSI were included. The primary outcomes were clinical cure, microbiological cure, and mortality. Secondary outcomes included adverse drug reactions (ADRs), hospital readmissions, treatment failure, emergency department visits, and length of hospital stay. Data analysis was performed using comprehensive meta-analysis software.

Results:
Nineteen studies were included with varied designs and clinical settings. Ceftriaxone showed no statistically significant difference in clinical cure [odds ratio (OR) 0.74, p = 0.391], microbiological cure (OR 0.94, p = 0.844), or 90-day mortality (OR 1.29, p = 0.498) compared with SOC. However, 30-day mortality was higher with ceftriaxone (OR 1.91, p = 0.004). Ceftriaxone demonstrated a nonsignificant trend toward fewer ADRs and lower hospital readmission rates.

Conclusion:
Ceftriaxone may offer comparable efficacy and improved convenience in the treatment of MSSA-BSI for selected patients, particularly in outpatient settings. However, the increased risk of 30-day mortality highlights the need for caution in critically ill populations. Further high-quality randomized trials are needed to clarify the role of ceftriaxone in MSSA-BSI management.

Key words: Ceftriaxone; MSSA; Bacteremia; Bloodstream infection; Antimicrobial therapy; Meta-analysis.

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Aimen Naz Articles by Taha Basit Ameen Articles by Furqanullah Khalid Articles by Abdul Raheem Articles by Mohammad Bilal Abbasi Articles by Syed Muhammad Sinaan Ali Articles by Syed Illyas Ahmed Articles by Maleeha Mehmood Articles by Syeda Zainab Fatima Rizvi Articles by Naeemullah Arbani Articles by Muhammad Saleem Khuhro
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Naz A, Ameen TB, Khalid F, Raheem A, Abbasi MB, Ali SMS, Ahmed SI, Mehmood M, Rizvi SZF, Arbani N, Khuhro MS. A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia. Int J Med Sci Public Health. 2026; 12(1): 13-25. doi:10.5455/IJMSPH.2026.v12.i1.2

Web Style

Naz A, Ameen TB, Khalid F, Raheem A, Abbasi MB, Ali SMS, Ahmed SI, Mehmood M, Rizvi SZF, Arbani N, Khuhro MS. A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia. https://www.ijmsph.org/?mno=275380 [Access: January 31, 2026]. doi:10.5455/IJMSPH.2026.v12.i1.2

AMA (American Medical Association) Style

Naz A, Ameen TB, Khalid F, Raheem A, Abbasi MB, Ali SMS, Ahmed SI, Mehmood M, Rizvi SZF, Arbani N, Khuhro MS. A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia. Int J Med Sci Public Health. 2026; 12(1): 13-25. doi:10.5455/IJMSPH.2026.v12.i1.2

Vancouver/ICMJE Style

Naz A, Ameen TB, Khalid F, Raheem A, Abbasi MB, Ali SMS, Ahmed SI, Mehmood M, Rizvi SZF, Arbani N, Khuhro MS. A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia. Int J Med Sci Public Health. (2026), [cited January 31, 2026]; 12(1): 13-25. doi:10.5455/IJMSPH.2026.v12.i1.2

Harvard Style

Naz, A., Ameen, . T. B., Khalid, . F., Raheem, . A., Abbasi, . M. B., Ali, . S. M. S., Ahmed, . S. I., Mehmood, . M., Rizvi, . S. Z. F., Arbani, . N. & Khuhro, . M. S. (2026) A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia. Int J Med Sci Public Health, 12 (1), 13-25. doi:10.5455/IJMSPH.2026.v12.i1.2

Turabian Style

Naz, Aimen, Taha Basit Ameen, Furqanullah Khalid, Abdul Raheem, Mohammad Bilal Abbasi, Syed Muhammad Sinaan Ali, Syed Illyas Ahmed, Maleeha Mehmood, Syeda Zainab Fatima Rizvi, Naeemullah Arbani, and Muhammad Saleem Khuhro. 2026. A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia. International Journal of Medical Science and Public Health, 12 (1), 13-25. doi:10.5455/IJMSPH.2026.v12.i1.2

Chicago Style

Naz, Aimen, Taha Basit Ameen, Furqanullah Khalid, Abdul Raheem, Mohammad Bilal Abbasi, Syed Muhammad Sinaan Ali, Syed Illyas Ahmed, Maleeha Mehmood, Syeda Zainab Fatima Rizvi, Naeemullah Arbani, and Muhammad Saleem Khuhro. "A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia." International Journal of Medical Science and Public Health 12 (2026), 13-25. doi:10.5455/IJMSPH.2026.v12.i1.2

MLA (The Modern Language Association) Style

Naz, Aimen, Taha Basit Ameen, Furqanullah Khalid, Abdul Raheem, Mohammad Bilal Abbasi, Syed Muhammad Sinaan Ali, Syed Illyas Ahmed, Maleeha Mehmood, Syeda Zainab Fatima Rizvi, Naeemullah Arbani, and Muhammad Saleem Khuhro. "A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia." International Journal of Medical Science and Public Health 12.1 (2026), 13-25. Print. doi:10.5455/IJMSPH.2026.v12.i1.2

APA (American Psychological Association) Style

Naz, A., Ameen, . T. B., Khalid, . F., Raheem, . A., Abbasi, . M. B., Ali, . S. M. S., Ahmed, . S. I., Mehmood, . M., Rizvi, . S. Z. F., Arbani, . N. & Khuhro, . M. S. (2026) A systematic review and meta-analysis of ceftriaxone versus standard therapy for methicillin-susceptible Staphylococcus aureus bacteremia. International Journal of Medical Science and Public Health, 12 (1), 13-25. doi:10.5455/IJMSPH.2026.v12.i1.2

Author Login Reviewer Login About Publisher Open Access Policy Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Digital Archiving & Preservation Policies Statement of Informed Consent Terms of Use License Information Copyright Information

About International Journal of Medical Science and Public Health

Contact Information

How to cite this article